In this podcast episode, leading experts share key updates in the management of myelodysplastic syndromes (MDS) from ASH 2025. Amer Zeidan, MBBS, MHS, Yale School of Medicine, highlights data from the MAXILUS trial, new insights from the iMERGE study, and early findings with the anti-CLEC12A antibody bexmarilimab in high-risk disease, followed by Valeria Santini, MD, University of Florence, Florence, Italy, who discusses long-term outcomes from iMERGE and a post-hoc analysis of the COMMANDS trial comparing luspatercept with epoetin alfa. Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, provides perspective on the Phase III VERONA trial of azacitidine plus venetoclax, and Daniel Wiseman, MBChB, PhD, University of Manchester, Manchester, UK, presents results from the Phase II AMMO study in MDS-MPN overlap syndromes before Professor Santini returns to address current debates in MDS diagnosis and treatment.